Insight onto the pathophysiology and clinical complications of thalassemia intermedia

Hemoglobin

Volumn 33, Issue SUPPL. 1, 2009, Pages

  Cappellini, Maria D ^a   Musallam, Khaled M ^b   Taher, Ali T ^b,c  

^a UNIVERSITY OF MILAN   (Italy)

^b AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^c Chronic Care Center Hazmieh   (Lebanon)

Author keywords

Complications; Pathophysiology; Review; Thalassemia intermedia

Indexed keywords

ACETYLSALICYLIC ACID; ERYTHROPOIETIN; FOLIC ACID; GROWTH DIFFERENTIATION FACTOR 15; HEMOGLOBIN BETA CHAIN; HEMOGLOBIN F; HEMOGLOBIN GAMMA CHAIN; HYDROXYUREA; HYPOXIA INDUCIBLE FACTOR; LIVER ENZYME; PENTOXIFYLLINE; VON HIPPEL LINDAU PROTEIN; WARFARIN; ZINC;

ALPHA THALASSEMIA; ANEMIA; BETA THALASSEMIA; BLOOD TRANSFUSION; CHOLECYSTECTOMY; CHOLELITHIASIS; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; DEEP VEIN THROMBOSIS; DIABETES MELLITUS; EXTRAMEDULLARY HEMATOPOIESIS; FOLIC ACID DEFICIENCY; GALLSTONE; GENE MUTATION; GENOTYPE PHENOTYPE CORRELATION; HEART EJECTION FRACTION; HEART FAILURE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOGLOBIN BLOOD LEVEL; HEMOLYTIC ANEMIA; HEMOSIDEROSIS; HUMAN; HYPOGONADISM; HYPOTHYROIDISM; INTRAUTERINE GROWTH RETARDATION; IRON CHELATION; LEG ULCER; LEUKOPENIA; LUNG EMBOLISM; PATHOPHYSIOLOGY; PHENOTYPE; PORTAL VEIN THROMBOSIS; PREGNANCY COMPLICATION; PREMATURE LABOR; PULMONARY HYPERTENSION; RETICULOENDOTHELIAL SYSTEM; SPLENECTOMY; SPONTANEOUS ABORTION; THALASSEMIA; THALASSEMIA INTERMEDIA; THALASSEMIA MAJOR; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOSIS; TREATMENT PLANNING;

ANEMIA, HEMOLYTIC; BETA-GLOBINS; BETA-THALASSEMIA; ERYTHROPOIESIS; HUMANS; IRON OVERLOAD; MUTATION;

EID: 73949140285     PISSN: 03630269     EISSN: 1532432X     Source Type: Journal    
DOI: 10.3109/03630260903351528     Document Type: Conference Paper

References (72)

1. Weatherall DJ. Thalassaemia: the long road from bedside to genome. Nat Rev Genet. 2004;5: 625-631.
2. Sturgeon P, Itano HA, Bergren WR. Genetic and biochemical studies of intermediate types of Cooley's anaemia. Br J Haematol. 1955l;1:264-277.
3. Galanello R, Cao A. Relationship between genotype and phenotype. Thalassemia intermedia. Ann NY Acad Sci. 1998;850:325-333. (Pubitemid 128714088)
4. Weatherall D. The molecular basis for phenotypic variability of the common thalassaemias. Mol Med Today. 1995;1:15-20.
5. Taher A, Ismaeel H, Cappellini MD. Thalassaemia Intermedia: revisited. Blood Cells Mol Dis. 2006;37:12-20.
6. Cappellini MD, Cohen A, Eleftheriou A, et al. Guidelines for the Clinical Management of Thalassaemia. 2nd revised edition. Nicosia, Cyprus: Thalassaemia International Federation; 2008.
7. Camaschella C, Mazza U, Roetto A, et al. Genetic interactions in thalassemia intermedia: Analysis of beta-mutations, alpha-genotype, gamma-promoters, and beta-LCR hypersensitive sites 2 and 4 in Italian patients. Am J Hematol. 1995;48:82-87.
8. Camaschella C, Kattamis AC, Petroni D, et al. Different hematological phenotypes caused by the interaction of triplicated alpha-globin genes and heterozygous beta-thalassemia. Am J Hematol. 1997;55:83-88.
9. Sampietro M, Cazzola M, Cappellini MD, et al. The triplicated alpha-gene locus and heterozygous beta thalassaemia: A case of thalassaemia intermedia. Br J Haematol. 1983;55:709-710.
10. Beris P, Solenthaler M, Deutsch S, et al. Severe inclusion body beta-thalassaemia with haemolysis in a patient double heterozygous for beta(0)-thalassaemia and quadruplicated apla-globin gene arrangement of the anti-4.2 type. Br J Haematol. 1999;105:1074-1080.
11. Taher A, Shammaa D, Bazarbachi A, et al. Absence of JAK2 V617F mutation in thalassemia intermedia patients. Mol Biol Rep. 2009;36:1555-1557.
12. Weatherall DJ. Thalassemia intermedia: Cellular and molecular aspects. J Hematol. 2001;86: 186-188.
13. Ho PJ, Hall GW, Luo LY, et al. Beta-thalassaemia intermedia: is it possible consistently to predict phenotype from genotype? Br J Haematol. 1998;100:70-78.
14. Rund D, Oron-Karni P, Filon D, et al. Genetic analysis of beta-thalassemia intermedia in Israel: diversity of mechanisms and unpredictability of phenotype. Am J Hematol. 1997;54:16-22.
15. Phadke SR, Agarwal S. Phenotype score to grade the severity of thalassemia intermedia. Indian J Pediatr. 2003;70:477-481.
16. Camaschella C, Cappellini MD. Thalassemia intermedia. Haematologica. 1995;80:58-68.
17. Olivieri NF. The beta-thalassemias. N Engl J Med. 1999;341:99-109.
18. Cappellini MD, Cerino M, Marelli S, et al. Thalassemia intermedia: Clinical aspects and management. Haematologica. 2001;86:194-196.
19. Taher A, Abou-Mourad Y, Abchee A, et al. Pulmonary thromboembolism in beta-thalassemia intermedia: Are we aware of this complication? Hemoglobin. 2002;26:107-112.
20. Aessopos A, Farmakis D, Karagiorga M, et al. Cardiac involvement in thalassemia intermedia: A multicenter study. Blood. 2001;97:3411-3416.
21. Taher AT, Otrock ZK, Uthman I, et al. Thalassemia and hypercoagulability Blood Rev. 2008;22:283-292.
22. Ataga KI, Cappellini MD, Rachmilewitz EA. Beta-thalassaemia and sickle cell anaemia as paradigms of hypercoagulability. Br J Haematol. 2007;139:3-13.
23. Origa R, Galanello R, Ganz T, et al. Liver iron concentrations and urinary hepcidin in b-thalassemia. Haematologica. 2007;92:583-588.
24. Tanno T, Bhanu NV, Oneal PA, et al. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat Med. 2007;13:1096-1101.
25. Valore EV, Ganz T. Posttranslational processing of hepcidin in human hepatocytes is mediated by the prohormone convertase furin. Blood Cells Mol Dis. 2008;40:132-138.
26. Silvestri L, Pagani A, Camaschella C. Furin-mediated release of soluble hemojuvelin: A new link between hypoxia and iron homeostasis. Blood. 2008;111:924-931.
27. Peyssonnaux C, Zinkernagel AS, Schuepbach RA, et al. Regulation of iron homeostasis by the hypoxia-inducible transcription factors (HIFs). J Clin Invest. 2007;117:1926-1932.
28. Pakbaz Z, Fischer R, Fung E, et al. Serum ferritin underestimates liver iron concentration in transfusion independent thalassemia patients as compared to regularly transfused thalassemia and sickle cell patients. Pediatr Blood Cancer. 2007;49:329-332.
29. Borgna-Pignatti C, Rigon F, Merlo L, et al. Thalassemia minor, the Gilbert mutation, and the risk of gallstones. Haematologica. 2003;88:1106-1109.
30. Chehal A, Aoun E, Koussa S, et al. Hypertransfusion: A successful method of treatment in thalassemia intermedia patients with spinal cord compression secondary to extramedullary hematopoiesis. Spine. 2003;28:E245-E249.
31. Castelli R, Graziadei G, Karimi M, et al. Intrathoracic masses due to extramedullary hematopoiesis. Am J Med Sci. 2004;328:299-303.
32. Smith PR, Manjoney DL, Teitcher JB, et al. Massive hemothorax due to intrathoracic extramedullary hematopoiesis in a patient with thalassemia intermedia. Chest. 1988;94:658-660.
33. Saxon BR, Rees D, Olivieri NF. Regression of extramedullary haemopoiesis and augmentation of fetal haemoglobin concentration during hydroxyurea therapy in beta thalassaemia. Br J Haematol. 1998;101:416-419.
34. Cario H, Wegener M, Debatin KM. Treatment with hydroxyurea in thalassemia intermedia with paravertebral pseudotumors of extramedullary hematopoiesis. Ann Hematol. 2002;81:478-482.
35. Gupta VL, Choubey BS. RBC survival, zinc deficiency, and efficacy of zinc therapy in sickle cell disease. Birth Defects Orig Artic Ser. 1987;23:477-483.
36. Dettelbach HR, Aviado DM. Clinical pharmacology of pentoxifylline with special reference to its hemorrheologic effect for the treatment of intermittent claudication. J Clin Pharmacol. 1985;25:8-26.
37. al Momen AK. Recombinant human erythropoietin induced rapid healing of a chronic leg ulcer in a patient with sickle cell disease. Acta Haematol. 1991;86:46-48.
38. Gimmon Z, Wexler MR, Rachmilewitz EA. Juvenile leg ulceration in beta-thalassemia major and intermedia. Plast Reconstr Surg. 1982;69:320-325.
39. Taher A, Isma'eel H, Mehio G, et al. Prevalence of thromboembolic events among 8,860 patients with thalassaemia major and intermedia in the Mediterranean area and Iran. Thromb Haemost. 2006;96:488-491.
40. Cappellini MD, Robbiolo L, Bottasso BM, et al.. Venous thromboembolism and hypercoagulability in splenectomized patients with thalassaemia intermedia. Br J Haematol. 2000;111:467-473.
41. Pignatti BC, Carnelli V, Caruso V, et al. Thromboembolic events in beta thalassemia major: An Italian multicenter study. Acta Haematol. 1998;99:76-79.
42. Manfre L, Giarratano E, Maggio A, et al. MR imaging of the brain: findings in asymptomatic patients with thalassemia intermedia and sickle cell-thalassemia disease. AJR Am J Roentgenol. 1999;173:1477-1480.
43. Atichartakarn V, Likittanasombat K, Chuncharunee S, et al. Pulmonary arterial hypertension in previously splenectomized patients with beta-thalassemic disorders. Int J Hematol. 2003;78:139-145.
44. Aessopos A, Farmakis D, Deftereos S, et al. Thalassemia heart disease: A comparative evaluation of thalassemia major and thalassemia intermedia. Chest. 2005;127:1523-1530.
45. Gharzuddine WS, Kazma HK, Nuwayhid IA, et al. Doppler characterization of left ventricular diastolic function in beta-thalassaemia major. Evidence for an early stage of impaired relaxation. Eur J Echocardiogr. 2002;3:47-51.
46. Isma'eel H, Chafic AH, Rassi FE, et al. Relation between iron-overload indices, cardiac echo-Doppler, and biochemical markers in thalassemia intermedia. Am J Cardiol. 2008;102:363-367.
47. Derchi G, Forni GL, Formisano F, et al. Efficacy and safety of sildenafil in the treatment of severe pulmonary hypertension in patients with hemoglobinopathies. Haematologica. 2005;90:452-458.
48. Savona-Ventura C, Bonello F. Beta-thalassemia syndromes and pregnancy. Obstet Gynecol Surv. 1994;49:129-137.
49. Skordis N, Christou S, Koliou M, et al. Fertility in female patients with thalassemia. J Pediatr Endocrinol Metab. 1998;11:35-943.
50. Karagiorga-Lagana M. Fertility in thalassemia: the Greek experience. J Pediatr Endocrinol Metab. 1998;11:945-951.
51. Nassar A, Naja M, Cesaretti C, et al. Pregnancy outcome in patients with beta-thalassemia intermedia at two tertiary care centers, in Beirut and Milan. Haematologica. 2008;93:1586-1587.
52. Cadili A, de Gara C. Complications of splenectomy. Am J Med. 2008;121:371-375.
53. Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica. 2004;89:1187-1193.
54. Aessopos A, Kati M, Meletis J. Thalassemia intermedia today: Should patients regularly receive transfusions? Transfusion. 2007;47:792-800.
55. Eder AF, Chambers LA. Noninfectious complications of blood transfusion. Arch Pathol Lab Med. 2007;13:708-718.
56. Cossu P, Toccafondi C, Vardeu F, et al. Iron overload and desferrioxamine chelation therapy in beta-thalassemia intermedia. Eur J Pediatr. 1981;137:267-271.
57. Pootrakul P, Sirankapracha P, Sankote J, et al. Clinical trial of deferiprone iron chelation therapy in beta-thalassaemia/haemoglobin E patients in Thailand. Br J Haematol. 2003;122:305-310.
58. Olivieri NF. Reactivation of fetal hemoglobin in patients with beta-thalassemia. Semin Hematol. 1996;33:24-42.
59. Arruda VR, Lima CS, Saad ST, et al. Successful use of hydroxyurea in beta-thalassemia major. N Engl J Med. 1997;336:964.
60. Bradai M, Abad MT, Pissard S, et al. Hydroxyurea can eliminate transfusion requirements in children with severe beta-thalassemia. Blood. 2003;102:1529-1530.
61. Dixit A, Chatterjee TC, Mishra P, et al. Hydroxyurea in thalassemia intermedia-a promising therapy. Ann Hematol. 2005;84:441-446.
62. Karimi M, Darzi H, Yavarian M. Hematologic and clinical responses of thalassemia intermedia patients to hydroxyurea during 6 years of therapy in Iran. J Pediatr Hematol Oncol. 2005;27:380-385.
63. Perrine SP, Ginder GD, Faller DV, et al. A short-term trial of butyrate to stimulate fetalglobin-gene expression in the beta-globin disorders. N Engl J Med. 1993;328:81-86.
64. Cappellini MD, Graziadei G, Ciceri L, et al. Oral isobutyramide therapy in patients with thalassemia intermedia: results of a phase II open study. Blood Cells Mol Dis. 2000;26:105-111.
65. Sher GD, Ginder GD, Little J, et al. Extended therapy with intravenous arginine butyrate in patients with beta-hemoglobinopathies. N Engl J Med. 1995;332:1606-1610.
66. Collins AF, Pearson HA, Giardina P, et al. Oral sodium phenylbutyrate therapy in homozygous beta thalassemia: A clinical trial. Blood. 1995;85:43-49.
67. Olivieri NF, Rees DC, Ginder GD, et al. Treatment of thalassaemia major with phenylbutyrate and hydroxyurea. Lancet. 1997;350:491-492.
68. Piga A, Longo F, Voi V, et al. Late effects of bone marrow transplantation for thalassemia. Ann NY Acad Sci. 1998;850:294-299.
69. Apperley JF. Bone marrow transplant for the haemoglobinopathies: past, present and future. Baillieres Clin Haematol. 1993;6:299-325.
70. Uckan D, Cetin M, Yigitkanli I, et al. Life-threatening neurological complications after bone marrow transplantation in children. Bone Marrow Transplant. 2005;35:71-76.
71. Khojasteh NH, Zakernia M, Ramzi M, et al. Bone marrow transplantation for hematological disorders-Shiraz experience. Indian J Pediatr. 2002;69:31-32.
72. Rund D, Rachmilewitz E. Advances in the pathophysiology and treatment of thalassemia. Crit Rev Oncol Hematol. 1995;20:237-254.